Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585633 | 0.86 | MAPK1 (0.49) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL31215206 | 0.84 | KDM4E (0.49) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL18549701 | 0.83 | KDM4E (0.46) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL18549674 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL15492956 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL18549636 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL7709349 | 0.77 | GAA (0.43) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL7706361 | 0.77 | HCRTR2 (0.62) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL31215231 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KDM4EGAAHPGDMAPK1 | |
| SCHEMBL21577704 | 0.74 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAAGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10092584-B2 | Compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035360-A1 | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2011138266-A1 | INDOLIZINE AND IMIDAZOPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092584-B2 | Compounds for the treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 3300/4885KDM4E 4533/4885GAA 1837/4885 |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | ALDH1A1 3300/4885KDM4E 4533/4885GAA 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.